Treatment with fezolinetant resulted in statistically significant reductions in the frequency and severity of VMS and improvements in quality of life The study met the four coprimary efficacy ...
The expanded partnership with ClinEdge will bring industry-sponsored trials to Skylight Health’s clinics in Colorado; Skylight announces the award of its first clinical trial in Colorado as part of ...
SALT LAKE CITY--(BUSINESS WIRE)--As the country marks the National Day of Prayer, a new study reveals insights about the habits and attitudes Americans have about prayer. The National Day of Prayer ...
TORONTO, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (NASDAQ:SLHG;TSXV:SLHG) (“Skylight Health” or the “Company”), a healthcare platform combining technology, and analytics focused on ...
The study met the four coprimary efficacy endpoints. Fezolinetant 30 and 45 mg once daily demonstrated statistically significant improvements from baseline in VMS frequency and severity at 4 and 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results